Ask AI
Zipalertinib for EGFR ex20ins Mutated NSCLC
REZILIENT1: Zipalertinib in Patients With EGFR ex20ins–Mutated NSCLC After Prior Platinum-Based Chemotherapy ± Amivantamab

Released: June 09, 2025

Expiration: December 08, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 09, 2025

Expiration: December 08, 2025